Navigation Links
European-wide study confirms benefits of D-penicillamine and trientine for Wilson disease
Date:3/31/2011

Results from the first ever European-wide retrospective analysis presented today at the International Liver CongressTM have shown both D-penicillamine and trientine continue to be effective treatments, providing positive survival rates in patients with Wilson disease free from a liver transplant.

Wilson disease is a rare genetic storage disorder in which copper is not excreted by the body effectively, leading to excess copper build up, liver failure and damage to the brain (neurological problems). Worldwide the condition, affects approximately one in 30,000 people. If not treated, Wilson disease can be chronically debilitating and life threatening. While current guidelines recommend the use of chelating agents (D-penicillamine, trientine) as first line therapy of symptomatic patients, optimal treatment regimens are yet to be established.

In this retrospective multicentre cohort study the long-term outcomes of treatment with D-penicillamine and trientine were reviewed in 347 patients with the condition. Changes of medication were common in both groups and resulted in a total of 467 analysed treatments (D-penicillamine, n=326, trientine n=141). Following an average follow-up of 16.5 years, both treatments provided a similar and excellent survival rate and prevented disease progression with the need for liver transplantation in over 98% of patients.

Daniele Prati, EASL's Scientific Committee Member and Press Committee Chairman commented: "Not only does this study show that both treatments are effective options for patients with this rare and often debilitating condition, but it is also encouraging to see how European countries can work together and exchange data which is extremely valuable to guide best practice and evaluate existing treatment regimens. Research on rare liver diseases presents remarkable interest."

"To date, a very limited number of drugs for these conditions are marketed, leaving the majority of rare diseases w
'/>"/>

Contact: Dimple Natali
easlpressoffice@cohnwolfe.com
44-790-013-8904
European Association for the Study of the Liver
Source:Eurekalert

Page: 1 2

Related biology news :

1. UC Riverside researcher receives $9 million USDA grant to study potato and tomato disease
2. New study shows you can have your candy and eat it too -- without adverse health effects
3. Study: Emissions trading doesnt cause pollution hot spots
4. Butterfly study reveals traits and genes associated with establishment of new populations
5. Study shows hunger hitting closer to home
6. Most states unclear about storage, use of babies blood samples, new study finds
7. GPS study shows wolves more reliant on a cattle diet
8. Russian boreal forests undergoing vegetation change, study shows
9. Spicing up your love life possible, study finds
10. Study finds weight training safe for pregnant women
11. Study predicts large regional changes in farmland area
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/14/2015)... YORK , May 14, 2015 /PRNewswire/ ... in identity verification and online remote proctoring, ... a software-as-a-service (SaaS) company and creator of ... customers of the two companies will benefit ... in Canvas. As a fully ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/7/2015)... Sweden , May 7, 2015 ... touch fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest ... and FPC1035 are mainly considered for integration on ... size gives smartphone OEMs increased possibilities to integrate ... The decreased size also improves possibilities for module ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... rates are concentrated in the northern part of the ... according to a report in Cancer Epidemiology, Biomarkers ... for Cancer Research. Ahmedin Jemal, D.V.M., Ph.D., vice ... said the decrease in death rates ranged from about ...
... global cooling and warming over the past few million ... they do today, according to a new study by ... The researchers, who analyzed California gray whale ( Eschrichtius ... 120,000 years, also found evidence to support the idea ...
... Move over, boy bands of Americathere,s a new ... Middle School in San Diego, California, entered The Christopher ... (STEM) program that challenges middle-school students to identify a ... Taking a cue from the popular group the Backstreet ...
Cached Biology News:Southern US states lag in reducing death rates from colorectal cancer 2Gray whales likely survived the Ice Ages by changing their diets 2Gray whales likely survived the Ice Ages by changing their diets 3Gray whales likely survived the Ice Ages by changing their diets 4Gray whales likely survived the Ice Ages by changing their diets 5Middle-school students educate community on proper computer posture 2
(Date:5/26/2015)... GERMANY (PRWEB) May 26, 2015 ... R. Grace & Co. (NYSE: GRA) announces that ... good manufacturing practice (GMP) certification from EXCiPACT™, an ... of pharmaceutical excipients. , All three ... of pharmaceutical grade excipient silica gels have now ...
(Date:5/26/2015)... und HILDEN, Deutschland, May 26, 2015 /PRNewswire/ ... ®   ermöglicht klinischen ... Erstellung dazugehöriger Berichte; Vorstellung auf den Konferenzen ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... von QIAGEN Clinical Insight ® (QCI™) ...
(Date:5/26/2015)... 2015  Sangamo BioSciences, Inc. (NASDAQ: SGMO ) announced ... will provide an update on the progress of Sangamo,s ZFP ... company,s business strategy at 1:30pm ET on Monday, June 1, ... is being held in New York, NY ... may be accessed via a link on the Sangamo BioSciences ...
(Date:5/26/2015)...  Alere Inc. (NYSE: ALR ) (the "Company") announced ... file its Quarterly Report on Form 10-Q for the three ... received a notice from the New York Stock Exchange (the ... NYSE,s continued listing requirements under the timely filing criteria established ... The reason for the delay relates to Company,s ...
Breaking Biology Technology:CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2
... members help guide non-profit on path to cure ... Project, a Minnesota,non-profit organization created to expedite the ... attracted two well-known experts to its,Board of Directors: ... (Logo: http://www.newscom.com/cgi-bin/prnh/20071214/CLF057LOGO-b ), Steven D. ...
... 16 Celator Pharmaceuticals today,announced that John Bennett, ... the BIO Business Forum during the Biotechnology Industry,Organization ... will,provide a corporate overview and an update on ... on Wednesday, June 18,2008 at 3:30 PDT in ...
... NovaVision today announced,the appointment of Rudy Mazzocchi as ... is responsible for leveraging the company,s novel,technology to ... patients with,impaired vision have access to NovaVision(R) Vision ... expertise bringing new medical technologies,and devices to market ...
Cached Biology Technology:Spring Point Project Names New Members to Board of Directors 2NovaVision Appoints Medical Technology Veteran Rudy Mazzocchi as Chief Executive Officer 2NovaVision Appoints Medical Technology Veteran Rudy Mazzocchi as Chief Executive Officer 3
Request Info...
... is ideal for both radioactive and nonradioactive ... Provides five pre-mixed nucleotide solutions for ... >10 8 cpm/g control DNA using ... the performance of the system Labels ...
ABI 432 Resins • Gln(Trt) Peptide Synthesis Column...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: